Search tool

Displaying 621 - 630 of 4575

Cover of publication

Document library

Mini-European web survey on drugs — Impact of COVID-19 on drug use, acquisition behaviour and the drug market in Luxembourg

This study presents the results of a web survey investigatng the impact of the COVID-19 related restrictions on drug consumption patterns and drug acquisition behaviours among a targeted convenience sample of recreational...

European Commission proposes to control two harmful new psychoactive substances

Today, the European Commission has proposed to control two harmful new psychoactive substances (NPS) across the European Union. The substances in question — MDMB-4en-PINACA and 4F-MDMB-BICA — are both synthetic cannabinoids, which...

ISSUP Greece Launch Event

This Webinar introduces the new National Chapter in Greece in regards to what ISSUP has to offer worldwide and in Greece in particular. Key speakers, among them Mr Alexis Goosdeel, EMCDDA Director...

Cover of the risk assessment of 4F MDMB BICA

Report on the risk assessment of a new psychoactive substance: methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dime- thylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

This publication presents the data and findings of the risk assessment on methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (4F-MDMB-BICA), carried out by the extended Scientific Committee of the EMCDDA on 9 December 2020. On the basis...

Cover of the risk assessment of MDMB 4en PINACA

Report on the risk assessment of a new psychoactive substance: methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (MDMB-4en-PINACA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

This publication presents the data and findings of the risk assessment on methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (MDMB-4en-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 9 December 2020. On the basis...

Expert Panel ECDC & EMCDDA PWID Guidance - Part I

11.03.2021 to 12.03.2021

The Expert Panel ECDC & EMCDDA PWID Guidance - Part I, takes place the 11-12 March. It is an EMCDDA initiative funded by the EU4Monitoring Drugs (EU4MD) project.

Minimal drug-treatment data set: coordination and data collection in Western Balkan partners – TDI satellite meeting

The treatment demand indicator (TDI) is one of the five EMCDDA key epidemiological indicators. The TDI collects information on the number of people entering treatment for a drug problem and offers a...

EMCDDA expert meeting

European Web Survey on Drugs online group meeting

The European Web Survey on Drugs (EWSD) has already been implemented in 2016 and 2017 in a total of 16 European countries. The next round of the EWSD will run in 2021...

EMCDDA expert meeting

cover EMCDDA trendspotter briefing March 2021 Impact of COVID-19 on drug use and drug services in Western Balkans

EMCDDA trendspotter briefing: Impact of COVID-19 on drug use and drug services in Western Balkans

The Western Balkans (Albania, Bosnia and Herzegovina, Kosovo*, Montenegro, North Macedonia and Serbia) registered the main waves of COVID-19 infections later than most of the EU countries, but containment strategies were implemented...

Launch of report EMCDDA trendspotter briefing: Impact of COVID-19 on drug use and drug services in Western Balkans

The EMCDDA launches a briefing report on the 'Impact of COVID-19 on drug use and drug services in Western Balkans'. Download the report >>